Danaher Q2 revenue, adjusted EPS beats on life sciences segment strength; raises outlook

Danaher Corporation

Danaher Corporation

DHR

0.00


Overview

  • US life sciences and diagnostics firm's Q2 revenue rose, beating analyst expectations

  • Adjusted EPS for Q2 grew 8% and beat analyst expectations

  • Company raised full-year adjusted EPS guidance after strong Q2 and Masimo acquisition


Outlook

  • Danaher expects Q3 2026 non-GAAP core revenue growth of 2.0% to 3.0% year-over-year

  • Company raises full-year 2026 adjusted diluted EPS guidance to $8.45-$8.60

  • Danaher expects full-year 2026 non-GAAP core revenue growth of 3.0% to 4.0% year-over-year


Result Drivers

  • LIFE SCIENCES STRENGTH - Life Sciences segment delivered its strongest quarter in several years, per CEO Rainer M. Blair

  • BIOPROCESSING ORDERS - Bioprocessing revenue was impacted by customer project timing, but orders grew mid-teens and underlying trends remained strong, per CEO

  • MASIMO ACQUISITION - Earlier-than-anticipated completion of Masimo acquisition enabled increased full-year adjusted EPS guidance


Company press release: ID:nPnb1mTsZa


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

Beat

$6.27 bln

$6.10 bln (20 Analysts)

Q2 Adjusted EPS

Beat

$1.94

$1.83 (22 Analysts)

Q2 EPS

$1.23

Q2 Operating Cash Flow

$1.50 bln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 24 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for Danaher Corp is $237.50, about 18.1% above its July 20 closing price of $201.11

  • The stock recently traded at 23 times the next 12-month earnings vs. a P/E of 22 three months ago


Reuters Recommended Reads

  • July 20 - Tempus to acquire Personalis for $1.5 billion

  • July 21 - Switzerland's Novartis beats Q2 sales estimates on strong sales across priority brands

  • July 20 - Cardinal Health to buy AdaptHealth diabetes unit, Strive Medical for $360 million


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.